

COVID-19 Vaccine Market - Global Outlook and Forecast 2021-2024

<https://marketpublishers.com/r/CDDDB90B23BDFEN.html>

Date: March 2021

Pages: 207

Price: US\$ 3,750.00 (Single User License)

ID: CDDDB90B23BDFEN

Abstracts

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Covid-19 Vaccine Market Report

The global COVID-19 vaccine market by revenue is expected to reach a value of USD 5 billion during 2021–2024.

VACCINE PIPELINE INSIGHTS

The global COVID-19 vaccine market size is expected to reach over 5 billion by 2024. Constant focus by government agencies and several vaccine manufacturers to prevent human and economic losses due to the COVID-19 virus across the world is expected to boost the market's growth. With several vendors implementing new strategies, including combining the phase 1 & 2 clinical trial stages and faster regulatory approvals from health agencies, the availability of vaccine doses across the globe is likely to grow during the forecast period.

The following factors are likely to contribute to the growth of the COVID-19 market during the forecast period:

Increased Initiatives for COVID-19 Vaccination

The emergence of Next Generation Vaccine Platforms for COVID-19 Vaccine

Fast Regulatory Approvals for COVID-19 Vaccines

The study considers the COVID-19 vaccine market's present scenario and its market dynamics for the forecast period 2022-2024. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Global COVID-19 Vaccine Market Segmentation

The global Covid-19 vaccine market research report includes a detailed segmentation by technology, geography. Protein-based vaccines constitute the highest COVID-19 vaccine market share as they contain the purified pieces of pathogen rather than the whole pathogen to trigger the immune response. In the absence of any significant adverse effect on the human body, these vaccines are likely to observe substantial growth during the forecast period. Novavax, Chinese Academy, and GSK/Sanofi are the major manufacturers that have approved protein-based vaccines for emergency use authorization. Protein-based vaccines can be used in patients with compromised immune responses.

By Technology

Vector-based

Nucleic acid-based

Protein-based

Whole Virus

INSIGHTS BY GEOGRAPHY

The outbreak of the COVID-19 pandemic was witnessed across the globe. Countries such as the UK, the US, Italy, Spain, India, China were the most affected; however, Middle East and African countries observed a low to moderate occurrence rate. The APAC market dominated the global COVID-19 vaccine market with over 58% share, followed by Europe with 15% and North America with 12%. The Middle East and Africa, and Latin America accounted for 10 % and 6%, respectively. Since the outbreak of the disease in 2019, which eventually was declared a pandemic by the WHO in March 2020, the spread has been thick and fast, swaying country after country and region after

region.

By Geography

North America

US

Canada

Europe

UK

Germany

France

Spain

Italy

Russia

APAC

China

Japan

South Korea

India

Australia

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

Egypt

UAE

Turkey

INSIGHTS BY VENDORS

AstraZeneca, GlaxoSmithKline, Moderna, Gamaleya, Bharat Biotech, and Pfizer are the major manufacturers of COVID-19 vaccines. Biotechnology and pharmaceutical industries are intensely competitive and are characterized by rapid and significant technological progress in vaccine development. Multiple products have been approved by the USFDA, EU, and other regulatory bodies for emergency use authorization (EUA) worldwide. Many products are manufactured using the latest vaccine platforms in the market.

Prominent Vendors

AstraZeneca

GlaxoSmithKline

Moderna

Gamaleya

Bharat Biotech

Pfizer

Johnson & Johnson

BioNTech

CureVac

Serum Institute of India

Novavax

Sinovac

Sinopharm

Upcoming Vendors

AnGes

AIVITA Biomedical

CanSinoBio

EuBiologics

Genexine

GreenLight Biosciences

Genova

Heat Biologics

INOVIO

IIBR

Medicago

Symvivo

Valneva

Zydus Cadila

KEY QUESTIONS ANSWERED

1. Which manufacturers are coming up with COVID-19 vaccines in 2021?
2. What are the major challenges faced by vendors in the distribution of the COVID-19 vaccine?
3. What is the size of the COVID-19 vaccine market by 2021?
4. Who are the major market players?
5. Which regions are likely to generate the largest revenues in 2021?

Contents

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 Market Definition

4.1.1 Inclusions

4.1.2 Exclusions

4.2 Base Year

4.3 Scope Of The Study

4.3.1 Market Segmentation by Geography

5 REPORT ASSUMPTIONS & CAVEATS

5.1 Key Caveats

5.2 Currency Conversion

5.3 Market Derivation

6 MARKET AT A GLANCE

7 INTRODUCTION

7.1 Overview

8 MARKET OPPORTUNITIES & TRENDS

8.1 Upcoming COVID-19 Vaccines

8.2 COVID-19 Vaccine Initiatives

8.3 Emergence of Next-Generation Vaccine Platforms

9 MARKET GROWTH ENABLERS

9.1 Faster Regulatory Approvals Of COVID-19 Vaccine

9.2 Rise In Number Of COVID-19 Patients

9.3 Contract Manufacturers Accelerating COVID-19 Vaccine Production

10 MARKET RESTRAINTS

10.1 COVID-19 Vaccine Distribution Among LMICs

10.2 Adverse Events & Negative Impact Of Approved Vaccines

10.3 Low Acceptance Of COVID-19 Vaccine

11 MARKET LANDSCAPE

11.1 Market Overview

11.2 COVID-19 Vaccine Pipeline

11.3 Market Size & Forecast

11.4 COVID-19 Supply Chain

11.5 Role of Contract Manufacturers in Manufacturing COVID-19 Vaccines

11.6 Five Forces Analysis

11.6.1 Threat of New Entrants

11.6.2 Bargaining Power of Suppliers

11.6.3 Bargaining Power of Buyers

11.6.4 Threat of Substitutes

11.6.5 Competitive Rivalry

12 TECHNOLOGY

12.1 Overview

12.2 Vector-Based COVID-19 Vaccine

12.2.1 Overview

12.3 Nucleic Acid-Based COVID-19 Vaccine

12.3.1 Overview

12.4 Protein-Based COVID-19 Vaccine

12.4.1 Overview

12.5 Whole Virus COVID-19 Vaccine

12.5.1 Overview

13 GEOGRAPHY

13.1 Market Snapshot & Growth Engine

13.2 Geographic Overview

14 APAC

- 14.1 Market Overview
- 14.2 Market Size & Forecast
- 14.3 Key Countries
 - 14.3.1 China: Market Size & Forecast
 - 14.3.2 India: Market Size & Forecast
 - 14.3.3 Japan: Market Size & Forecast
 - 14.3.4 South Korea: Market Size & Forecast
 - 14.3.5 Australia: Market Size & Forecast

15 EUROPE

- 15.1 Market Overview
- 15.2 Market Size & Forecast
- 15.3 Key Countries
 - 15.3.1 UK: Market Size & Forecast
 - 15.3.2 Germany: Market Size & Forecast
 - 15.3.3 Italy: Market Size & Forecast
 - 15.3.4 France: Market Size & Forecast
 - 15.3.5 Russia: Market Size & Forecast
 - 15.3.6 Spain: Market Size & Forecast

16 NORTH AMERICA

- 16.1 Market Overview
- 16.2 Market Size & Forecast
- 16.3 Key Countries
 - 16.3.1 US: Market Size & Forecast
 - 16.3.2 Canada: Market Size & Forecast

17 MIDDLE EAST & AFRICA

- 17.1 Market Overview
- 17.2 Market Size & Forecast
- 17.3 Key Countries
 - 17.3.1 Turkey: Market Size & Forecast
 - 17.3.2 Saudi Arabia: Market Size & Forecast

- 17.3.3 Egypt: Market Size & Forecast
- 17.3.4 South Africa: Market Size & Forecast
- 17.3.5 UAE: Market Size & Forecast

18 LATIN AMERICA

- 18.1 Market Overview
- 18.2 Market Size & Forecast
- 18.3 Key Countries
 - 18.3.1 Brazil: Market Size & Forecast
 - 18.3.2 Mexico: Market Size & Forecast

19 COMPETITIVE LANDSCAPE

- 19.1 Competition Overview
 - 19.1.1 AstraZeneca
 - 19.1.2 Moderna
 - 19.1.3 Gamaleya
 - 19.1.4 Pfizer
 - 19.1.5 Johnson & Johnson
 - 19.1.6 GlaxoSmithKline
 - 19.1.7 Novavax
 - 19.1.8 Bharath Biotech
 - 19.1.9 CureVac
 - 19.1.10 Serum Institute of India
 - 19.1.11 Sinovac
 - 19.1.12 Sinopharm

20 KEY COMPANY PROFILES

- 20.1 AstraZeneca
 - 20.1.1 Business Overview
 - 20.1.2 Product Offerings
 - 20.1.3 Key Strategies
 - 20.1.4 Key Strengths
 - 20.1.5 Key Opportunities
- 20.2 GlaxoSmithKline
 - 20.2.1 Business Overview
 - 20.2.2 Product Offerings

20.2.3 Key Strategies

20.2.4 Key Strengths

20.2.5 Key Opportunities

20.3 Moderna

20.3.1 Business Overview

20.3.2 Product Offerings

20.3.3 Key Strategies

20.3.4 Key Strengths

20.3.5 Key Opportunities

20.4 Gamaleya

20.4.1 Business Overview

20.4.2 Product Offerings

20.4.3 Key Strategies

20.4.4 Key Strengths

20.4.5 Key Opportunities

20.5 Bharat Biotech

20.5.1 Business Overview

20.5.2 Product Offerings

20.5.3 Key Strategies

20.5.4 Key Strengths

20.5.5 Key Opportunities

20.6 Pfizer

20.6.1 Business Overview

20.6.2 Product Offerings

20.6.3 Key Strategies

20.6.4 Key Strengths

20.6.5 Key Opportunities

20.7 Johnson & Johnson

20.7.1 Business Overview

20.7.2 Product Offerings

20.7.3 Key Strategies

20.7.4 Key Strengths

20.7.5 Key Opportunities

20.8 BioNTech

20.8.1 Business Overview

20.8.2 Product Offerings

20.8.3 Key Strategies

20.8.4 Key Strengths

20.8.5 Key Opportunities

20.9 CureVac

20.9.1 Business Overview

20.9.2 Product Offerings

20.9.3 Key Strategies

20.9.4 Key Strengths

20.9.5 Key Opportunities

20.10 Serum Institute of India

20.10.1 Business Overview

20.10.2 Product Offerings

20.10.3 Key Strategies

20.10.4 Key Strengths

20.10.5 Key Opportunities

20.11 Novavax

20.11.1 Business Overview

20.11.2 Product Offerings

20.11.3 Key Strategies

20.11.4 Key Strengths

20.11.5 Key Opportunities

20.12 Sinovac

20.12.1 Business Overview

20.12.2 Product Offerings

20.12.3 Key Strategies

20.12.4 Key Strengths

20.12.5 Key Opportunities

20.13 Sinopharm

20.13.1 Business Overview

20.13.2 Product Offerings

20.13.3 Key Strategies

20.13.4 Key Strengths

20.13.5 Key Opportunities

21 UPCOMING VENDORS

21.1 AnGes

21.1.1 Business Overview

21.2 AIVITABiomedical

21.2.1 Business Overview

21.3 CanSinoBio

21.3.1 Business Overview

- 21.3.2 Product Offerings
- 21.4 eubiologics
 - 21.4.1 Business Overview
- 21.5 Genexine
 - 21.5.1 Business Overview
- 21.6 GreenLight Bioscience
 - 21.6.1 Business Overview
- 21.7 Gennova
 - 21.7.1 Business Overview
- 21.8 Heat Biologics
 - 21.8.1 Business Overview
- 21.9 INOVIO
 - 21.9.1 Business Overview
- 21.10 IIBR
 - 21.10.1 Business Overview
- 21.11 medicago
 - 21.11.1 Business Overview
- 21.12 Symvivo
 - 21.12.1 Business Overview
- 21.13 Valneva
 - 21.13.1 Business Overview
- 21.14 Zydus Cadila
 - 21.14.1 Business Overview

22 REPORT SUMMARY

- 22.1 Key Takeaways
- 22.2 Strategic Recommendations

23 QUANTITATIVE SUMMARY

- 23.1 Market By Geography
- 23.2 North America
- 23.3 Europe
- 23.4 APAC
- 23.5 Latin America
- 23.6 Middle East & Africa

24 APPENDIX

24.1 Abbreviations

List Of Exhibits

LIST OF EXHIBITS

- Exhibit 1 Global COVID-19 Vaccines Market
- Exhibit 2 Market Size Calculation Approach 2021
- Exhibit 3 Projected Manufacturing Capacity of Lead Companies Producing COVID-19 Vaccines by End of 2021 (in billions)
- Exhibit 4 Impact of Upcoming COVID-19 Vaccine
- Exhibit 5 Impact of COVID-19 Vaccine Initiatives
- Exhibit 6 Impact of Emergence of Next-Generation Vaccine Platforms
- Exhibit 7 Impact of Faster Regulatory Approvals of COVID-19 Vaccine
- Exhibit 8 Impact of Rise in Number of COVID-19 Patients
- Exhibit 9 COVID-19 Cases in Major Regions
- Exhibit 10 Impact of Contract Manufacturers Accelerating COVID-19 Vaccine Production
- Exhibit 11 Impact of COVID-19 Vaccine Distribution Among LMICs
- Exhibit 12 Income Classification by Confirmed Doses Purchased (\$ billions)
- Exhibit 13 Impact of Adverse Events & Negative Impact of Approved Vaccines
- Exhibit 14 Impact of Low Acceptance of COVID-19 Vaccine
- Exhibit 15 People Not Willing to Take COVID-19 Vaccine (% share)
- Exhibit 16 COVID-19 Vaccines Under Development by Dosage
- Exhibit 17 COVID-19 Vaccines Under Development by Route of Administration
- Exhibit 18 Global COVID-19 Vaccines Market 2021–2024 (\$ billion)
- Exhibit 19 COVID-19 Vaccine Logistics & Distribution
- Exhibit 20 COVID-19 Vaccine Development 2021 (% share)
- Exhibit 21 Five Forces Analysis 2021
- Exhibit 22 Incremental Growth by Geography 2021 & 2024
- Exhibit 23 Global COVID-19 Vaccines Market by Geography
- Exhibit 24 Global COVID-19 Vaccines Market 2021- 2024 (\$ million)
- Exhibit 25 Global COVID-19 Vaccines Market 2021- 2024 (% share)
- Exhibit 26 Production Capabilities of COVID-19 Vaccine Candidates Per Country (millions)
- Exhibit 27 Income Classification by Confirmed Number of Doses Purchased by Country (Doses in billions)
- Exhibit 28 APAC COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth
- Exhibit 29 COVID-19 Vaccines Market in APAC 2021–2024 (\$ billion)
- Exhibit 30 Incremental Growth in APAC 2021 & 2024

- Exhibit 31 COVID-19 Vaccines Market in China 2021–2024 (\$ million)
- Exhibit 32 COVID-19 Vaccines Market in India 2021–2024 (\$ million)
- Exhibit 33 COVID-19 Vaccines Market in Japan 2021–2024 (\$ million)
- Exhibit 34 COVID-19 Vaccines Market in South Korea 2021–2024 (\$ million)
- Exhibit 35 COVID-19 Vaccines Market in Australia 2021–2024 (\$ million)
- Exhibit 36 Europe COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth
- Exhibit 37 COVID-19 Vaccines Market in Europe 2021–2024 (\$ billion)
- Exhibit 38 Incremental Growth in Europe 2021 & 2024
- Exhibit 39 COVID-19 Vaccines Market in UK 2021–2024 (\$ million)
- Exhibit 40 COVID-19 Vaccines Market in Germany 2021–2024 (\$ million)
- Exhibit 41 COVID-19 Vaccines Market in Italy 2021–2024 (\$ million)
- Exhibit 42 COVID-19 Vaccines Market in France 2021–2024 (\$ million)
- Exhibit 43 COVID-19 Vaccines Market in Russia 2021–2024 (\$ million)
- Exhibit 44 COVID-19 Vaccines Market in Spain 2021–2024 (\$ million)
- Exhibit 45 North America COVID-19 Vaccine Market: Incremental Growth vs. Absolute Growth
- Exhibit 46 COVID-19 Vaccine Developers in North America
- Exhibit 47 COVID-19 Vaccines Market in North America 2021–2024 (\$ billion)
- Exhibit 48 Incremental Growth in North America 2021 & 2024
- Exhibit 49 COVID-19 Vaccines Market in US 2021–2024 (\$ million)
- Exhibit 50 COVID-19 Vaccines Market in Canada 2021–2024 (\$ million)
- Exhibit 51 Middle East & Africa COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth
- Exhibit 52 COVID-19 Vaccines Market in Middle East & Africa 2021–2024 (\$ billion)
- Exhibit 53 Incremental Growth in Middle East & Africa 2021 & 2024
- Exhibit 54 COVID-19 Vaccines Market in Turkey 2021–2024 (\$ million)
- Exhibit 55 COVID-19 Vaccines Market in Saudi Arabia 2021–2024 (\$ million)
- Exhibit 56 COVID-19 Vaccines Market in Egypt 2021–2024 (\$ million)
- Exhibit 57 COVID-19 Vaccines Market in South Africa 2021–2024 (\$ million)
- Exhibit 58 COVID-19 Vaccines Market in UAE 2021–2024 (\$ million)
- Exhibit 59 Latin America COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth
- Exhibit 60 COVID-19 Vaccine Market in Latin America 2021–2024 (\$ billion)
- Exhibit 61 Incremental Growth in Latin America 2021 & 2024
- Exhibit 62 COVID-19 Vaccines Market in Brazil 2021–2024 (\$ million)
- Exhibit 63 COVID-19 Vaccines Market in Mexico 2021–2024 (\$ million)
- Exhibit 64 AstraZeneca Revenue 2017-2019 (\$million)
- Exhibit 65 AstraZeneca Research & Development Expenditure (\$ million)

- Exhibit 66 GlaxoSmithKline Revenue 2017-19 (billions)
- Exhibit 67 Moderna Revenue 2017-2019 (\$ million)
- Exhibit 68 Moderna Research & Development Expenditure (\$ million)
- Exhibit 69 Pfizer Revenue 2017- 2019 (\$ billion)
- Exhibit 70 Pfizer Research & Development 2017- 2019 (\$ billion)
- Exhibit 71 Johnson & Johnson Revenue 2017- 2019 (\$ million)
- Exhibit 72 Johnson & Johnson Research & Development 2017- 2019 (\$ million)
- Exhibit 73 BioNTech Revenue 2017- 2019 (million)
- Exhibit 74 BioNTech Research & Development 2017- 2019 (\$ million)
- Exhibit 75 Novavax Revenue 2017-2019 (million)
- Exhibit 76 Novavax Research &Development Expenditure 2017-2019 (million)

List Of Tables

LIST OF TABLES

- Table 1 Key Caveats
- Table 2 Currency Conversion 2013?2020
- Table 3 Up-Coming COVID-19 Vaccines
- Table 4 Comparison of Up-Coming COVID-19 Vaccine Platforms
- Table 5 COVID-19 Cases in Top Ten Countries
- Table 6 COVID-19 Vaccines EUA Approved as of Mid of 2021 January
- Table 7 COVID-19 Vaccines Approved for Use in Various Countries
- Table 8 COVID-19 Candidates in Clinical Phase Based on Vaccines Types
- Table 9 List of COVID-19 Vaccines Under Phase II & III Clinical Trial
- Table 10 List of COVID-19 Vaccines Under Phase I & II Clinical Trial
- Table 11 List of COVID-19 Vaccines Under Phase I & Pre-Clinical Trial
- Table 12 Key companies & CMOs Agreements for COVID-19 Vaccine (millions)
- Table 13 EUA-Approved COVID-19 Vaccines
- Table 14 COVID-19 Vaccines Based on Vector Platform Under Development
- Table 15 COVID-19 Vaccines Based on Nucleic Acid Platform Under Development
- Table 16 COVID-19 Vaccines Based on Protein Platform Under Development
- Table 17 COVID-19 Vaccines Based on Whole Virus Platform Under Development
- Table 18 Regional Confirmed COVID-19 Cases WHO (as of 2021 February)
- Table 19 Countries with Highest COVID-19 Cases & Deaths
- Table 20 List of Agreements Signed for COVID-19 Vaccines
- Table 21 Approved Vaccines for COVID-19 in UK
- Table 22 UK Agreement with Companies for COVID-19 Vaccine (million)
- Table 23 List of Agreements Signed for COVID-19 Vaccines
- Table 24 Approved Vaccines for COVID-19 in US
- Table 25 US Agreement with Companies for COVID-19 Vaccine (million)
- Table 26 List of Agreements Signed for COVID-19 Vaccines
- Table 27 List of Agreements Signed for COVID-19 Vaccines.
- Table 28 List of Agreements Signed for COVID-19 Vaccines with AstraZeneca
- Table 29 List of Agreements Signed for COVID-19 Vaccines with Moderna
- Table 30 List of Agreements Signed for COVID-19 Vaccines with Pfizer
- Table 31 List of Agreements Signed for COVID-19 Vaccines with Johnson & Johnson
- Table 32 List of Agreements Signed for COVID-19 Vaccines with GSK
- Table 33 List of Agreements Signed for COVID-19 Vaccines with Novavax
- Table 34 List of Agreements Signed for COVID-19 Vaccines with CureVac
- Table 35 List of Agreements Signed for COVID-19 Vaccines with SinoVac

Table 36 AstraZeneca: Major Product Offerings

Table 37 GlaxoSmithKline: Major Product Offerings

Table 38 Moderna: Major Product Offerings

Table 39 Gamaleya: Major Product Offerings

Table 40 Bharat Biotech: Major Product Offerings

Table 41 Pfizer: Major Product Offerings

Table 42 Johnson & Johnson: Major Product Offerings

Table 43 BioNTech: Major Product Offerings

Table 44 CureVac: Major Product Offerings

Table 45 Serum Institute of India: Major Product Offerings

Table 46 Novavax: Major Product Offerings

Table 47 Sinovac: Major Product Offerings

Table 48 Sinopharm: Major Product Offerings

Table 49 CanSinoBio: Major Product Offerings

Table 50 Global COVID-19 Vaccines Market by Geography 2021?2024 (\$ million)

Table 51 Global COVID-19 Vaccines Market by Geography 2021?2024 (%)

Table 52 North America COVID-19 Vaccines Market 2021?2024 (\$ million)

Table 53 North America COVID-19 Vaccines Market 2021?2024 (%)

Table 54 Europe COVID-19 Vaccines Market 2021?2024 (\$ million)

Table 55 Europe COVID-19 Vaccines Market 2021?2024 (%)

Table 56 APAC COVID-19 Vaccines Market 2021?2024 (\$ million)

Table 57 APAC COVID-19 Vaccines Market 2021?2024 (%)

Table 58 Latin America COVID-19 Vaccines Market 2021?2024 (\$ million)

Table 59 Latin America COVID-19 Vaccines Market 2021?2024 (%)

Table 60 Middle East & Africa COVID-19 Vaccines Market 2021?2024 (\$ million)

Table 61 Middle East & Africa COVID-19 Vaccines Market 2021?2024 (%)

I would like to order

Product name: COVID-19 Vaccine Market - Global Outlook and Forecast 2021-2024

Product link: <https://marketpublishers.com/r/CDDDB90B23BDFEN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CDDDB90B23BDFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970